



an Open Access Journal by MDPI

## Advances in Urothelial Cancer Volume II

Guest Editors:

### Dr. Ho Kyung Seo

Department of Urology,  
Chonnam National University  
Medical School, Chonnam  
National University Hwasun  
Hospital, Gwangju, Republic of  
Korea

### Prof. Dr. Eu Chang Hwang

Department of Urology,  
Chonnam National University  
Medical School, Chonnam  
National University Hwasun  
Hospital, Gwangju, Republic of  
Korea

### Dr. Whi-An Kwon

Department of Urology, Myongji  
Hospital, Hanyang University  
College of Medicine, 55, Hwasu-  
ro, 14 beon-gil, Deogyang-gu,  
Gyeonggi-do, Goyang-si 10475,  
Republic of Korea

Deadline for manuscript  
submissions:

**closed (31 October 2023)**

### Message from the Guest Editors

The use of immune checkpoint inhibitors, particularly with antibodies directed against programmed cell death 1 protein (PD-1) or its ligand (PD-L1), has led to important advances in the treatment of metastatic urothelial cancer and been tested in the early stages of bladder cancer. However, only a small number of patients respond to checkpoint inhibitors. Therefore, attempts are being made to develop biomarkers that could help to identify urothelial cancer patients who are likely to respond to these drugs.

As a type of targeted therapy, therapeutic agents such as enfortumab vedotin, an antibody-drug conjugate designed to treat Nectin-4 expressing cancer, and erdafitinib, a small molecule inhibitor of fibroblast growth factor receptor, have been accepted in clinical studies on metastatic bladder cancer.

In this Special Issue on “Advances in the Urothelial Cancer Volume II”, we will include the information and available data regarding molecular classification, diagnosis, immunotherapy, various targeted agents, and antibody-drug conjugates that have recently shown promising results against urothelial cancer.



[mdpi.com/si/153422](https://mdpi.com/si/153422)

# Special Issue



an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research  
Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA  
2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

*Biomedicines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](https://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
X@Biomed\_MDPI